SCHEMBL20705261

SCHEMBL20705261

CNC(=O)C(CCCCNC(N)=O)NC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 4/20 0.43
SIRT6 Q8N6T7 1/20 0.43
SIRT5 Q9NXA8 3/20 0.41
FOLH1 Q04609 1/20 0.38
BMP1 P13497 3/20 0.37
C3AR1 Q16581 1/20 0.37
SIRT2 Q8IXJ6 2/20 0.35
MMP1 P03956 2/20 0.35
MMP3 P08254 2/20 0.35
MMP8 P22894 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
NOD1 Q9Y239 1/20 0.34
GNAI3 P08754 1/20 0.34
GNAO1 P09471 1/20 0.34
GNAI1 P63096 1/20 0.34
TLR2 O60603 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19115851 0.89 SIRT1 (0.42) SIRT1SIRT6SIRT5FOLH1BMP1
SCHEMBL20705255 0.86 FOLH1 (0.52) SIRT1SIRT6SIRT5FOLH1BMP1
SCHEMBL24531193 0.82 C3AR1 (0.38) SIRT1SIRT6SIRT5BMP1C3AR1
SCHEMBL20705272 0.80 SIRT6 (0.47) SIRT1SIRT6FOLH1BMP1MMP1
SCHEMBL24831913 0.80 NOD1 (0.41) SIRT1SIRT6SIRT5BMP1C3AR1
SCHEMBL22524830 0.80 C3AR1 (0.41) SIRT1SIRT6SIRT5BMP1C3AR1
SCHEMBL22690287 0.78 C3AR1 (0.44) SIRT5FOLH1C3AR1SIRT2CTDSP1
SCHEMBL22690289 0.78 C3AR1 (0.44) SIRT5FOLH1C3AR1SIRT2CTDSP1
SCHEMBL20705144 0.78 MMP1 (0.45) SIRT1SIRT6FOLH1BMP1MMP1
SCHEMBL23394645 0.78 DPP7 (0.40) SIRT1SIRT6SIRT5BMP1C3AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199602-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-06-20 US disclosed
US-11905285-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-02-20 US disclosed
US-20220056028-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-02-24 US disclosed
US-11168083-B2 Inhibitors of Plasma Kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-11-09 US disclosed
US-20200239463-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF DYAX CORP. (US) 2020-07-30 US disclosed
EP-3661922-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF Dyax Corp. (US) 2020-06-10 EP disclosed
WO-2019028362-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF DYAX CORP. (US) 2019-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199602-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 SIRT1 1885/4885SIRT6 1850/4885SIRT5 1627/4885
US-11168083-B2 Inhibitors of Plasma Kallikrein and uses thereof KLKB1, KLK1, KLK5 SIRT1 1885/4885SIRT6 1850/4885SIRT5 1627/4885
US-20200239463-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 SIRT1 1885/4885SIRT6 1850/4885SIRT5 1627/4885
US-20220056028-A1 INHIBITORS OF PLASMA KALLIKREIN AND USES THEREOF KLKB1, KLK1, KLK5 SIRT1 1885/4885SIRT6 1850/4885SIRT5 1627/4885
US-11905285-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 SIRT1 1885/4885SIRT6 1850/4885SIRT5 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.